PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS
Purpose. Pharmacoeconomic rationale for the use of sorafenib in malignant tumors in comparison with drugs that are included in the list of pharmaceuticals to provide to certain categories of citizens.Method of the study. Pharmacoeconomic rationale for the use of sorafenib in this study is made by an...
Saved in:
Main Authors: | M. Y. Frolov, N. A. Avksentjev, I. G. Rusakov, E. V. Derkach |
---|---|
Format: | Article |
Language: | Russian |
Published: |
QUASAR, LLC
2016-09-01
|
Series: | Исследования и практика в медицине |
Subjects: | |
Online Access: | https://www.rpmj.ru/rpmj/article/view/146 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01) -
Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and/or hepatic vein tumor thrombosis
by: Yirui Zhai, et al.
Published: (2025-03-01) -
Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation
by: Chunxiao Li, et al.
Published: (2025-01-01) -
ANGPTL3 overcomes sorafenib resistance via suppression of SNAI1 and CPT1A in liver cancer
by: Yang-Hsiang Lin, et al.
Published: (2025-02-01) -
Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States
by: Finn RS, et al.
Published: (2025-02-01)